DNA Synthesizer Market, By Product Type (Benchtop DNA Synthesizers, Automated DNA Synthesizers), By Application (Gene Synthesis, Oligonucleotide Synthesis, Next-Generation Sequencing (NGS) Library Preparation, Drug Development, Others (DNA labeling, aptamer synthesis, synthetic biology)), By Synthesis Scale (Small-Scale DNA Synthesis, Medium-Scale DNA Synthesis, Large-Scale DNA Synthesis), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROs), Forensic Laboratories, Others (government organizations, diagnostic laboratories)), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
The Global DNA Synthesizer Market size is projected to reach US$ 15.60 Billion by 2030, from US$ 4.3 Billion in 2023, at a CAGR of 20.2% during the forecast period 2023-2030.
The growth of the DNA synthesizer market is being driven by the increasing demand for DNA synthesis in research and development (R&D), diagnostics, and drug discovery. DNA synthesis is a process of creating DNA molecules from scratch. It is used in a variety of applications, including the development of new drugs, the diagnosis of diseases, and the creation of genetically modified organisms.
The increasing demand for DNA synthesis in R&D is being driven by the growing understanding of the human genome and the development of new gene-editing technologies. DNA synthesis is used to create custom DNA sequences that can be used to study gene function, develop new drugs, and create genetically modified organisms.
DNA Synthesizer Market Regional Insights
North America is expected to dominate the global DNA synthesizer market during the forecast period, with a share of over 35.0% in 2023. This is due to the presence of a large number of leading DNA synthesizer manufacturers and the high demand for DNA synthesis in the region. The U.S. is the largest market for DNA synthesizers in North America, followed by Canada.
Europe is expected to be the second-largest market for DNA synthesizers, with a share of over 25.0% in 2023. This is due to the presence of a strong research and development (R&D) ecosystem in the region and the high demand for DNA synthesis in the pharmaceutical and biotechnology industries. Germany, the U.K., and France are the leading markets for DNA synthesizers in Europe.
Asia Pacific is expected to be the fastest-growing market for DNA synthesizers, with a CAGR of over 15.0% during the forecast period. This is due to the increasing demand for DNA synthesis in the region's pharmaceutical and biotechnology industries, as well as the growing number of research institutions in the region. China, India, and Japan are the leading markets for DNA synthesizers in Asia Pacific.
Analyst View’s
The DNA synthesizer is the instrument used for creating artificial DNA sequences. And, as per the research activity, it plays a crucial role in various fields such as genetic engineering, protein synthesis, and pharmaceutical development. Due to this, many investors are focusing on developing technologically advanced DNA synthesizer whiich could expand the market over the forecast period. These advancements in DNA synthesizer technology are expected to lead to increased efficiency and accuracy in creating artificial DNA sequences. Additionally, the growing demand for personalized medicine and the need for rapid drug discovery are driving the market for DNA synthesizers.
Figure 1. Global DNA Synthesizer Market Share (%), By Region, 2023
Advancements in Genetic Research: The field of genetic research has experienced significant advancements in recent years. DNA synthesizers play a crucial role in this research by enabling the synthesis of custom DNA sequences. The growing demand for DNA synthesis is driven by the need to study genetic variations and gene expression and develop new therapeutic modalities such as gene therapies and personalized medicine. For instance, on October 2, 2023, EVONETIX LTD, the Company developing semiconductor scale technology to improve access to gene synthesis, announced the introduction of new branding to align with its vision to ‘Redefine possible’ through the development and commercialization of its benchtop semiconductor gene synthesis platform. The rebrand follows a period of significant milestones, including external evaluation of Evonetix’s chip-synthesized DNA.
Increasing Demand for Synthetic Biology: Synthetic biology is an emerging field that combines biology and engineering principles to design and construct new biological parts, devices, and systems. DNA synthesis is a fundamental technology in synthetic biology, allowing scientists to create custom-designed DNA sequences and engineer biological systems. The rising interest in synthetic biology applications, such as biofuels, biopharmaceuticals, and bio-based materials, is fueling the demand for DNA synthesizers.
Growing Demand for Next-Generation Sequencing (NGS): Next-generation sequencing technologies have revolutionized genomic research by enabling high-throughput sequencing of DNA. DNA synthesizers are used in library preparation for NGS, where short DNA fragments are synthesized and amplified for sequencing. With the increasing adoption of NGS in various fields, including clinical diagnostics, agriculture, and drug discovery, the demand for DNA synthesizers is on the rise.
Declining Cost of DNA Synthesis: The cost of DNA synthesis has been decreasing steadily over the years, making it more accessible to researchers and scientists. Advancements in synthesis methods, automation, and scale-up processes have contributed to cost reductions. The affordability of DNA synthesizers has expanded their adoption in academic institutions, research laboratories, and biotechnology companies, driving market growth.
DNA Synthesizer Market Opportunities
Expansion of Personalized Medicine: Personalized medicine, which involves tailoring medical treatments to an individual's genetic makeup, holds great potential for improving patient outcomes. DNA synthesizers play a crucial role in generating custom DNA sequences for diagnostic tests, targeted therapies, and patient profiling. As personalized medicine gains wider adoption and becomes an integral part of healthcare, the demand for DNA synthesizers is expected to increase.
Rise of CRISPR Technology: The development and widespread adoption of CRISPR-Cas9 gene editing technology have revolutionized the field of genetic engineering. DNA synthesizers are essential for generating DNA templates and donor sequences required for CRISPR experiments. With the increasing application of CRISPR technology in research, therapeutics, and agriculture, the demand for DNA synthesizers is likely to grow.
Emergence of DNA Data Storage: DNA has emerged as a potential data storage medium due to its high density and long-term stability. DNA synthesizers are used to encode digital information into DNA sequences. As the demand for data storage continues to grow exponentially, exploring DNA-based data storage presents a significant opportunity for DNA synthesizer manufacturers.
Growing Adoption of Gene Therapies: Gene therapies hold immense promise for treating genetic disorders and certain types of cancers. DNA synthesizers are instrumental in the production of therapeutic DNA constructs and viral vectors used in gene therapy approaches. As gene therapies advance and become more mainstream, there will be an increased need for DNA synthesizers to support their development and manufacturing.
DNA Synthesizer Market Report Coverage
Report Coverage
Details
Base Year:
2022
Market Size in 2023:
US$ 4.3 Bn
Historical Data for:
2018 to 2022
Forecast Period:
2023 - 2030
Forecast Period 2023 to 2030 CAGR:
20.2%
2030 Value Projection:
US$ 15.60 Bn
Geographies covered:
North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East & Africa: GCC Countries, Israel, Rest of Middle East
Africa: South Africa, North Africa, and Central Africa
Segments covered:
By Product Type: Benchtop DNA Synthesizers, Automated DNA Synthesizers
By Application: Gene Synthesis, Oligonucleotide Synthesis, Next-Generation Sequencing (NGS) Library Preparation, Drug Development, Others (DNA labeling, aptamer synthesis, synthetic biology)
By Synthesis Scale: Small-Scale DNA Synthesis, Medium-Scale DNA Synthesis, Large-Scale DNA Synthesis
By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROs), Forensic Laboratories, Others (government organizations, diagnostic laboratories)
Companies covered:
Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Danaher Corporation (Integrated DNA Technologies), GenScript Biotech Corporation, Eurofins Genomics, LGC Limited, BioAutomation Corporation, Bio-Rad Laboratories, Twist Bioscience Corporation, Hamilton Company, New England Biolabs, Nippon Genetics, LGC Biosearch Technologies, DNA Script, Ribbon Biolabs GmbH, and Camena Bioscience
Growth Drivers:
Advancements in Genetic Research
Increasing Demand for Synthetic Biology
Growing Demand for Next-Generation Sequencing (NGS)
Increasing Demand for High-Throughput Synthesis: There is a growing need for DNA synthesizers that can perform high-throughput synthesis, allowing researchers to rapidly generate large quantities of custom DNA sequences. High-throughput synthesis enables applications such as library preparation for next-generation sequencing, large-scale gene assembly, and screening of DNA-based libraries for drug discovery. DNA synthesizer manufacturers are focusing on improving synthesis speed and scalability to meet this demand.
Advancements in Miniaturization and Portability: There is a trend towards the miniaturization and portability of DNA synthesizers. Compact and portable DNA synthesizers offer advantages such as increased flexibility, on-demand synthesis capabilities, and field-based applications. These portable systems are particularly useful in point-of-care diagnostics, field research, and resource-limited settings where access to a fully equipped laboratory may be limited.
Integration of Automation and Robotics: Automation and robotics technologies are being integrated into DNA synthesizers to streamline workflows and enhance efficiency. Automated systems can perform tasks such as reagent dispensing, mixing, and purification, reducing manual labor and minimizing human error. The integration of DNA synthesizers with robotic platforms enables high-throughput synthesis and improves reproducibility, making them ideal for large-scale research and industrial applications.
Adoption of Advanced Synthesis Methods: DNA synthesizers are utilizing advanced synthesis methods to improve the efficiency and accuracy of DNA synthesis. Enzymatic synthesis, which uses enzymes instead of traditional chemical methods, offers benefits such as higher fidelity and the ability to incorporate modified nucleotides. Photochemical synthesis, where light is used to activate nucleotide coupling, enables precise control over the synthesis process. These advanced synthesis methods are gaining traction in the DNA synthesizer market.
DNA Synthesizer Market Restraints
Cost of Instruments and Consumables: DNA synthesizers and associated consumables can be expensive, particularly for advanced models and high-throughput applications. The initial investment required to purchase DNA synthesizers, as well as the ongoing costs of reagents and cartridges, can pose a barrier to adoption, especially for smaller research laboratories and institutions with limited budgets.
Technical Complexity and Expertise Requirements: Operating DNA synthesizers and designing custom DNA sequences often require technical expertise and specialized training. The complexity of the instruments and the synthesis process can be challenging for researchers who are new to the field of DNA synthesis. This technical barrier may limit the widespread adoption of DNA synthesizers in certain settings.
Limitations in Sequence Length and Complexity: DNA synthesizers have inherent limitations in terms of the maximum sequence length and complexity they can handle. Synthesizing long DNA sequences or sequences with complex structures, such as repetitive regions or secondary structures, can be challenging. These limitations can restrict the range of applications and designs that can be achieved using DNA synthesizers.
Quality Control and Error Rates: DNA synthesis is susceptible to errors, including sequence inaccuracies, incomplete synthesis, and post-synthesis modifications. Quality control measures are crucial to ensuring the accuracy and reliability of synthesized DNA sequences. However, the need for rigorous quality control and the occurrence of errors can lead to additional time, costs, and potential setbacks in research and development projects.
Recent Developments
New product launches
SYNTAX DNA Printing Platform System (DNA Script, 2023): DNA Script, the worldwide leader in Enzymatic DNA Synthesis (EDS) technology, announced the broad commercial availability of the fully automated SYNTAX DNA printing platform, which consists of the benchtop STX-200 system, the latest biochemistry advancements, robust reagent kits, and intuitive software enhancements.
InfiniSynth Platform (Ribbon Biolabs GmbH, 2022): Ribbon Biolabs GmbH, the DNA synthesis company, announced the successful implementation of their innovative InfiniSynth platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes Biosolutions, a leading laboratory automation technology company. The InfiniSynth platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and biopharmaceutical development.
ENFINIA (Elegen Corporation, 2023): Elegen Corporation, a leader in DNA innovation, announced that it has successfully concluded its early access program and is now offering global commercial access to its new class of double-stranded DNA, developed to power the synthetic biology revolution. Elegen’s ENFINIA DNA represents a major advance in the field, offering an unprecedented combination of length, speed, and accuracy to streamline synthetic biology workflows and scale to meet the demands of the growing bioeconomy.
Acquisition, Partnerships, and Funding
On July 4, 2023, Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, closed a US$10mn Series A financing round. The new funding will be used to scale operations and continue the development of its DNA synthesis platform.
On January 9, 2023, Twist Bioscience Corporation, a public biotechnology company, announced a partnership with Astellas Pharma, a Japan multinational pharmaceutical company, seeking to discover antibodies against several targets to hit on curative therapies for hard-to-treat diseases. Twist Biosciences focuses on synthetic biology and genomics company to develop a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a technology for manufacturing synthetic DNA by “writing” DNA on a silicon chip. Under the terms of the agreement, Twist will conduct antibody discovery activities against multiple targets identified by Astellas. Besides upfront payment and project-specific research fees, Twist will be eligible to receive up to US$ 11 million per product through payments associated with defined clinical and commercial milestones.
In October 2022, DNA Script, a world leader in enzymatic DNA synthesis (EDS) for DNA on demand, signed distribution agreements in the Middle East with Gulf Scientific Corporation, a leading provider of complete laboratory solutions across the Middle East and Eisenberg Ltd., and Israel scientific instrument company, to expand its worldwide footprint of sales, service, and support. A new distribution partner, Kiko Tech, Ltd., a Japan analytical, medical and life science provider company, extends the company’s existing channel network in the Asia-Pacific (APAC) region.
In May 2022, DNA Script reached a distribution agreement with Premas Life Sciences, a biotechnology research company, which announced to expand DNA Script’s footprint and provide sales and support for the SYNTAX System DNA printer in labs in India. The SYNTAX System printer is the only commercial DNA manufacturing technology that utilizes the power of enzymatic DNA synthesis (EDS), which produces synthetic DNA without the toxic reagents and hazardous waste associated with older DNA printing methods.
In January 2022, Ribbon Biolabs, the DNA synthesis company, announced the successful close of EUR 18 million in its Series A funding round from a consortium of European and US investors led by Hadean Ventures, and with participation from Lansdowne Partners, Helicase Venture as well as several undisclosed investors. Existing investors IST cube and TECNET equity also joined in the round.
Figure 2. Global DNA Synthesizer Market Share (%), By product type, 2023
Definition: The DNA synthesizer market refers to the industry involved in the manufacturing and sale of instruments and equipment used for synthesizing DNA molecules. DNA synthesizers enable the automated production of custom DNA sequences, which find applications in various fields such as biotechnology, genetic engineering, drug discovery, diagnostics, and synthetic biology. These synthesizers are designed to accurately assemble nucleotides to create specific DNA sequences, facilitating research and development in molecular biology and genetic manipulation.
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
The global DNA Synthesizer Market size was valued at USD 4.3 billion in 2023 and is expected to reach USD 15.60 billion in 2030.
Cost of instruments and consumables, technical complexity and expertise requirements, limitations in sequence length and complexity, and quality control and error rates are hampering the market growth
The major factors driving the market growth include advancements in genetic research, increasing demand for synthetic biology, growing demand for next-generation sequencing (NGS), and declining cost of DNA synthesis.
The leading component segment in the market is the product type segment, which includes Benchtop DNA Synthesizers, and Automated DNA Synthesizers.
The major players operating in the market include Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Danaher Corporation (Integrated DNA Technologies), GenScript Biotech Corporation, Eurofins Genomics, LGC Limited, BioAutomation Corporation, Bio-Rad Laboratories, Twist Bioscience Corporation, Hamilton Company, New England Biolabs, Nippon Genetics, LGC Biosearch Technologies, DNA Script, Ribbon Biolabs GmbH, and Camena Bioscience.
U.S.: 
U.K. : 
India : 